ENVB
NASDAQ
US
Enveric Biosciences, Inc. - Common Stock
$2.03
▼ $-0.11
(-5.14%)
Vol 46K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.2M
ROE
-349.1%
Margin
-14.1%
D/E
0.00
Beta
0.29
52W
$4–$96
Wall Street Consensus
7 analysts · Feb 20262
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Earnings
Beat rate: 75.0%
Next Report
May 12, 2026
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | — | — | — |
| Dec 2024 | $-2.82 | $-57.60 | $-54.78 |
| Sep 2024 | $-95.47 | $-43.20 | +$52.27 |
| Jun 2024 | $-100.98 | $-45.00 | +$55.98 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$2.1M | -$3.2M | -$2.2M | -$2.5M | -$1.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -341.5% | -250.2% | -341.5% | -341.5% | -341.5% | -349.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -14.1% | -14.1% | -14.1% | -14.1% | -14.1% |
| Gross Margin | — | 20.4% | 20.4% | 20.4% | 20.4% | 20.4% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 2.43 | 4.08 | 2.43 | 2.43 | 2.43 | 4.60 |
Key Ratios
ROA (TTM)
-241.9%
P/S (TTM)
0.05
P/B
2.3
EPS (TTM)
$-89.80
CF/Share
$-10.58
Rev Growth 3Y
+3.4%
52W High
$96.36
52W Low
$4.11
$4.11
52-Week Range
$96.36
Financial Health
Free Cash Flow
-$2.1M
Cash
$3.8M
As of Sep 30, 2025
How does ENVB compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ENVB valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
0.1
▼
99%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
2.3
▲
8%
above
peers
(2.1)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ENVB profitability vs Pharmaceuticals peers
ROE
-349.1%
▼
543%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-14.1%
▲
70%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
20.4%
▼
70%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-241.9%
▼
546%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
ENVB financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
4.6
▲
37%
above
peers
(3.4)
vs Peers
vs Industry
Below avg
Beta
0.3
▼
70%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
ENVB fundamentals radar
ENVB
Peer median
Industry
ENVB profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ENVB vs peers: key metrics
Latest News
No related news yet